Chester County News and Community Website
GLENOLDEN, PA — The Charcot-Marie-Tooth Association (CMTA) has announced a $240,000 investment in gene replacement therapy targeting CMT4A, a severe form of the disease. This initiative, led by Dr. Xin …
CMTA Invests $240K in Gene Therapy for Rare Nerve Disorder Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a positive outcome from the Data and Safety Monitoring Board (DSMB) review of its Phase 1/2 ArMaDa clinical trial for OCU410, a …
Ocugen’s Gene Therapy Shows Promise in Early Trial for Age-Related Macular Degeneration Read More
PHILADELPHIA PA — Greater Philadelphia has emerged as a powerhouse in the cell and gene therapy industry, housing almost 10 percent of the world’s companies in this rapidly expanding sector. …
Greater Philadelphia Dominates Cell and Gene Therapy Landscape – A Beacon of Innovation and Employment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that Arun Upadhyay, PhD, Chief Scientific Officer and Head of Research & Development, will speak at the International Society for Cell & …
Ocugen’s Chief Scientific Officer to Present at International Cell & Gene Therapy Meeting Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a significant milestone in cancer treatment. The company recently dosed the first patient in its Phase 1 clinical trial of …
Carisma Therapeutics Launches First Human Trial for CAR-Monocyte Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on innovative therapies, announced the completion of dosing in the second cohort of its groundbreaking GARDian clinical trial for …
Ocugen Advances with Phase 1/2 Trial for Stargardt Disease Treatment Read More
WAYNE, PA — XyloCor Therapeutics, Inc. recently revealed the final results from the Phase 2 segment of its EXACT clinical trial at the Society for Cardiovascular Angiography & Interventions (SCAI) …
XyloCor Therapeutics Announces Promising Results for Gene Therapy in Treating Refractory Angina Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, announced that Dr. Benjamin Bakall will present findings from the OCU400 Phase 1/2 clinical trials at the upcoming Retinal Cell …
Ocugen to Present Pioneering Gene Therapy Data at Retinal Innovation Summit Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is poised to make a significant impact at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA, …
Ocugen to Spotlight Groundbreaking Gene Therapy Research at ARVO 2024 Read More
PARSIPPANY, NJ & KING OF PRUSSIA, PA — Ferring Pharmaceuticals has teamed up with SK pharmteco to scale up the commercial manufacturing capacity of ADSTILADRIN (nadofaragene firadenovec-vncg), a gene therapy …
Ferring Pharmaceuticals Partners with SK pharmteco to Boost Gene Therapy Supply Read More